抗血小板双联方案联合降脂治疗进展性脑梗死的临床研究

Clinical Research of Antiplatelet Duplex Plan and Lipid-lowering Treatment of Progressive Cerebral Infarction

目的研究抗血小板双联方案联合降脂治疗进展性脑梗死的临床价值。方法方便选取该院2014年5月—2015年5月收治的70例进展性脑梗死患者为研究对象,将患者抽签随机分为观察组与对照组,每组35例。观察组给予氯吡格雷、阿司匹林联合阿托伐他汀钙片治疗,对照组给予单纯阿托伐他汀钙片治疗,比较两组凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)等凝血指标及不良反应发生率。结果观察组APTT(38.16±1.89)s长于对照组,FIB(1.96±0.37)g/L低于对照组,且NIHSS评分(6.89±1.35)分低于对照组(11.73±1.68)分,FIM评分(81.37±9.16)分高于对照组(66.26±7.53)分,差异有统计学意义(P<0.05)。观察组与对照组治疗后PT分别为(12.03±2.76)、(12.43±2.98)s,且不良反应发生率分别为4.29%、2.86%,差异无统计学意义(P>0.05)。结论阿司匹林、氯吡格雷联合阿托伐他汀钙治疗进展性脑梗死可提高患者独立能力,降低神经功能缺失程度,改善凝血功能,降低血栓形成风险,安全性好,具有较好的临床应用价值。

Objective To research the clinical value of antiplatelet duplex plan and lipid-lowering treatment of progressive cerebral infarction. Methods 70 cases of patients with progressive cerebral infarction admitted and treated in our hospital from May 2014 to May 2015 were convenient selected and randomly divided into two groups with 35 cases in each, the observation group were treated with clopidogrel, aspirin combined with atorvastatin calcium tablets, while the control group were only treated with atorvastatin calcium tablets, and the PT, APTT, FIB and incidence rate of adverse reactions were compared between the two groups. Results The APTT in the observation group was(38.16±1.89)s, which was longer than that in the control group, and the FIB was(1.96±0.37)g/L, which was lower than that in the control group, and the NIHSS score was(6.89±1.35)points, which was lower than that in the control group [(11.73±1.68)points], and the FIM score was higher than that in the control group[(81.37±9.16)points vs(66.26±7.53)points], and the difference was statistically significant(P<0.05), after treatment, the PT in the observation group and the control group was respectively(12.03±2.76)s and(12.43±2.98)s, and the incidence rate of adverse reactions was respectively 4.29% and 2.86%, and the difference was not statistically significant(P>0.05). Conclusion The antiplatelet duplex plan and lipid-lowering treatment of progressive cerebral infarction can improve the independent ability of patients, reduce the nerve function defect degree, improve the coagulation function and reduce the risk of thrombus with good safety, which is of better clinical application value.